DSM Venturing
VC Fund
Heerlen, The Netherlands
DSM Venturing is a VC fund in Heerlen focused on Health Care and Biotechnology. Founded in 2002, DSM Venturing is the corporate venture capital arm of Royal DSM, based in Heerlen, Netherlands. The firm invests in companies developing innovative products and services in sectors of life sciences (animal and human health & nutrition) and biomedical.
- Total investments:
- 94
- Last investment:
- Lead investor:
- 51%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries DSM Venturing invests in
Stages DSM Venturing invests in
Countries DSM Venturing invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.5M–$32M
- Series B
- $5.6M–$30M
Investment Focus
Industry
- Health Care 27 (29%)
- Biotechnology 26 (28%)
- Manufacturing 15 (16%)
- Medical Device 9 (10%)
- Wellness 8 (9%)
Stage
- Series A 30 (32%)
- Funding Round 18 (19%)
- Series B 16 (17%)
- Seed 8 (9%)
- Series C 8 (9%)
Country
- United States 37 (39%)
- Canada 5 (5%)
- Israel 5 (5%)
- United Kingdom 5 (5%)
- The Netherlands 5 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Akshat Kshetrapal
Investment Director
|
Investment Director | Total investments: 3 | Find email | |
Arpesh Mehta
Investment Director
|
Investment Director | Total investments: 3 | Find email | |
Greg McParland
Investment Director
|
Investment Director | Total investments: 1 | Find email | |
Iulian Baxan
Analyst
|
Analyst | Total investments: 0 | Find email | |
Luda Kopeikina
Investment Director
|
Investment Director | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $5.9M / Series A / Jan 22, 2026 | |
Athian
|
Athian enables animal agriculture producers to monetize their sustainability efforts — whether it's past work or progress towards a future sustainability goal. | $4M / Series A / Nov 19, 2025 | |
Meala Foodtech
|
Meala Foodtech develops functional proteins for multiple meat replacements. Meala uses naturally occurring biocatalysts to treat plant-based proteins. | Seed / Jun 03, 2025 | |
Vivici
|
Vivici is a B2B ingredients firm that provides nutritious and sustainable animal-free dairy proteins manufactured with precision fermentation to food and beverage manufacturers. | $34.2M / Series A / Feb 25, 2025 | |
NutriLeads
|
NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers. | $4.9M / Series C / Dec 18, 2023 | |
|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $4.7M / Series A / Nov 08, 2023 | |
|
Vivici
|
Vivici is a B2B ingredients firm that provides nutritious and sustainable animal-free dairy proteins manufactured with precision fermentation to food and beverage manufacturers. | Seed / Aug 14, 2023 | |
Meatable
|
Meatable is a food production company that produces guilt-free meat. Meatable is a company that creates manufactured meat using stem cell technology. By employing pluripotent stem cells, which have the potential to transform any type of cell from muscle to fat without serum, the company's method eliminates the need to remove any tissue from ananimal, allowing consumers to have sustainable food. | $34M / Series B / Aug 07, 2023 | |
Incredo
|
DouxMatok is a food-tech company. They have developed a proprietary technology that enhances the sweetness of sugars with no after taste - preserving the full "sugar experience" customers are looking for. The enhanced sweetness allows for a significant reduction in the consumption of sugar.The company was incorporated in 2014, and itsR&D center is based in Petach-Tikva, Israel. | $30M / Series C / May 24, 2023 | |
VitaminLab
|
VitaminLab takes your health history, our nutrient testing or health data, and uses our matching algorithm to create an all-in-one personalized supplement that impacts your health. The company, run by a team of pharmacists and health care professionals, was founded to change the status quo of the supplement industry. | Series A / May 08, 2023 | |
| See all 94 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does DSM Venturing invest in?
DSM Venturing invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series A and Funding Round stage. Most of the 94 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is DSM Venturing's check size?
DSM Venturing typically joins rounds of $3.5M–$32M at Series A and $5.6M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DSM Venturing participates in.
How do I contact DSM Venturing?
Public channels for DSM Venturing include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DSM Venturing?
The team at DSM Venturing includes Akshat Kshetrapal (Investment Director), Arpesh Mehta (Investment Director) and Greg McParland (Investment Director), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
